Casdin Capital, LLC Buys Magenta Therapeutics Inc, Foundation Medicine Inc, Blueprint Medicines Corp, Sells iShares Nasdaq Biotechnology Index Fund, Evolent Health Inc, Jounce Therapeutics Inc

• New Purchases: MGTA, BLFS, NTGN, CDNA,
• Added Positions: FMI, BPMC, MYOK, BLUE, OSUR, CRSP, ALNY, CLVS, EDIT, FIXX,
• Reduced Positions: EVH, GBT, JNCE, GNMK,
• Sold Out: IBB, ADVM,

For the details of Casdin Capital, LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Casdin+Capital%2C+LLC

1. Foundation Medicine Inc (FMI) - 685,000 shares, 13.1% of the total portfolio. Shares added by 31.73%
2. Loxo Oncology Inc (LOXO) - 360,000 shares, 8.73% of the total portfolio.
3. Blueprint Medicines Corp (BPMC) - 635,000 shares, 5.64% of the total portfolio. Shares added by 82.47%
4. Sage Therapeutics Inc (SAGE) - 250,000 shares, 5.47% of the total portfolio.
5. MyoKardia Inc (MYOK) - 780,000 shares, 5.42% of the total portfolio. Shares added by 39.29%

Casdin Capital, LLC initiated holding in Magenta Therapeutics Inc. The purchase prices were between $13.5 and $14.52, with an estimated average price of $14.11. The stock is now traded at around $13.22. The impact to a portfolio due to this purchase was 3.84%. The holding were 2,035,818 shares as of 2018-06-30.

Casdin Capital, LLC initiated holding in BioLife Solutions Inc. The purchase prices were between $6.18 and $13.49, with an estimated average price of $9.08. The stock is now traded at around $20.81. The impact to a portfolio due to this purchase was 1.6%. The holding were 1,000,000 shares as of 2018-06-30.

Casdin Capital, LLC initiated holding in Neon Therapeutics Inc. The purchase prices were between $12.6 and $15, with an estimated average price of $13.69. The stock is now traded at around $12.00. The impact to a portfolio due to this purchase was 0.6%. The holding were 338,345 shares as of 2018-06-30.

Casdin Capital, LLC initiated holding in CareDx Inc. The purchase prices were between $7.93 and $15.79, with an estimated average price of $11.44. The stock is now traded at around $17.03. The impact to a portfolio due to this purchase was 0.34%. The holding were 200,000 shares as of 2018-06-30.

Casdin Capital, LLC added to a holding in Foundation Medicine Inc by 31.73%. The purchase prices were between $69.95 and $136.75, with an estimated average price of $90.69. The stock is now traded at around $137.00. The impact to a portfolio due to this purchase was 3.16%. The holding were 685,000 shares as of 2018-06-30.

Casdin Capital, LLC added to a holding in Blueprint Medicines Corp by 82.47%. The purchase prices were between $60.96 and $101.18, with an estimated average price of $79.51. The stock is now traded at around $68.44. The impact to a portfolio due to this purchase was 2.55%. The holding were 635,000 shares as of 2018-06-30.

Casdin Capital, LLC added to a holding in MyoKardia Inc by 39.29%. The purchase prices were between $44.9 and $51.75, with an estimated average price of $48.43. The stock is now traded at around $57.30. The impact to a portfolio due to this purchase was 1.53%. The holding were 780,000 shares as of 2018-06-30.

Casdin Capital, LLC added to a holding in bluebird bio Inc by 37.93%. The purchase prices were between $153.85 and $197, with an estimated average price of $175.92. The stock is now traded at around $158.70. The impact to a portfolio due to this purchase was 1.21%. The holding were 200,000 shares as of 2018-06-30.

Casdin Capital, LLC added to a holding in OraSure Technologies Inc by 166.67%. The purchase prices were between $14.46 and $18.08, with an estimated average price of $16.89. The stock is now traded at around $16.47. The impact to a portfolio due to this purchase was 0.92%. The holding were 640,000 shares as of 2018-06-30.

Casdin Capital, LLC added to a holding in CRISPR Therapeutics AG by 62.96%. The purchase prices were between $42.62 and $73.59, with an estimated average price of $56.78. The stock is now traded at around $48.92. The impact to a portfolio due to this purchase was 0.7%. The holding were 220,000 shares as of 2018-06-30.

Casdin Capital, LLC sold out a holding in iShares Nasdaq Biotechnology Index Fund. The sale prices were between $101.03 and $113.9, with an estimated average price of $106.96.

Casdin Capital, LLC sold out a holding in Adverum Biotechnologies Inc. The sale prices were between $5.3 and $6.9, with an estimated average price of $6.01.